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This paper compares the blood-to-serum distribution (B/S ratio) of
3,4-methylenedioxymethamphetamine (MDMA) and its major
metabolite 3,4-methylenedioxyamphetamine (MDA). B/S ratios
were determined by liquid chromatography–tandem mass
spectrometry analysis following liquid–liquid extraction as a
function of the hematocrit value (experimental specimens) and in
blood and corresponding serum samples (n = 63) from 16 healthy
volunteers participating in a controlled driving experiment
(authentic specimens). A regression analysis to calculate the B/S
ratio was performed followed by an analysis of covariances
(ANCOVA). A linear relationship between the hematocrit value
and the B/S ratio of both MDMA and MDA could be established
from the experimental data. For MDMA, the regressions provided
mean B/S ratios of 1.22 and 1.26 for the experimental setting and
the authentic samples, respectively. For MDA, the analysis
determined slopes of 1.15 and 1.27 for the experimental setting
and field study, respectively. ANCOVA revealed that the method of
determination (experimental vs. authentic specimens) did not
influence the resulting slopes. A conversion factor of 0.80 may
give an adequate estimate to derive the serum concentration for
MDMA if only the concentration in whole blood is known,
whereas such a definitive factor could not be established for MDA
because of its very low levels in authentic samples.
Introduction
The designer drug 3,4-methylenedioxymethamphetamine
(MDMA, ecstasy) accounts for about 9 million users of central
stimulants world-wide, approximately one-third of them in
Europe. This exceeds use levels for cocaine and heroin, com-
bined (1). Among other things, MDMA consumption leads to
decreased ability of risk assessment combined with reckless
behavior and is thus of interest in driving under the influence
(DUI) cases (2). MDMA is metabolized to 3,4-methylene-
dioxyamphetamine (MDA) via N-demethylation, mostly by the
cytochrome P450 enzymes CYP2D6 (3) and, to a minor extent,
CYP1A2 (4). MDA is still pharmacologically active and the only
metabolite found in serum or plasma, with concentrations of
typically 5–10% of the corresponding MDMA levels (5).
Many drugs of forensic interest, such as ∆9-tetrahydro-
cannabinol (THC) and 11-carboxy-THC (6,7), tricyclic anti-
depressants (8), benzodiazepines (8–11), and opiates (12–14),
show an unequal distribution between blood serum and cel-
lular phase. Ratios may not only vary between different com-
pounds with the same core structure, but also between the
parent drug and corresponding metabolites (8) or depend on
the hematocrit value (13,15). Except for THC, 11-carboxy-THC
(16), ethanol (15), and, more recently, benzodiazepines (11),
distribution studies have mostly been performed in vitro on
supplemented samples after separation of plasma or serum and
red blood cells by either equilibrium dialysis (17) or centrifu-
gation. As plasma or serum samples are seldom available in
forensic investigations, MDMA and MDA are generally deter-
mined from whole blood samples. Knowing the distribution
of MDMA and MDA into the major subcompartments of blood
is mandatory in order to reliably compare whole blood to
plasma or serum levels that have been derived from controlled
pharmacokinetic studies. For MDMA and MDA, as well, it is
not known how far off from the true values the in vitro deter-
mined ones are likely to be.
This paper compares the blood-to-serum distribution (B/S
ratio) of MDMA and MDA in both an experimental setting and
using authentic samples from healthy volunteers conducting
a DUI experiment under the influence of MDMA.
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Abstract
Technical Note
Materials and Methods
Experimental (in vitro) setting
Fresh blood was drawn by venous puncture from a healthy
volunteer (S-Monovette, Sarstedt, Nümbrecht, Germany).
After determination of the hematocrit value by centrifugation,
the sample was split. A smaller aliquot was put aside while the
remaining sample was centrifuged for 10 min at 3000 × g
(Megafuge 1.0 R, Heraeus Sepatech, Osterode, Germany). The
supernatant and packed erythrocytes were separated; liquid
and cellular phases were combined to yield different hemat-
ocrit values (n = 3) largely covering the physiological range.
The original and the combined samples were spiked with
MDMA and MDA [200 (one sample) or 250 ng/mL]. A prelim-
inary study revealed that the B/S ratio was not dependent on
the concentration (50–500 ng/mL; data not shown). Follow-
ing equilibration (30 min), about one-third of the sample was
then directly extracted; the remaining liquid was again cen-
trifuged (10 min, 3000 × g). Five aliquots of whole blood and
recovered serum were extracted independently after addition
of internal standards (MDMA-d5 and MDA-d5). Mean values and
standard deviations were recorded.
Authentic samples (field study)
Blood and corresponding serum samples from 16 healthy vol-
unteers of a driving experiment were provided from the Exper-
imental Psychopharmacology Unit, Maastricht University. This
study was conducted according to the code of ethics on human
experimentation established by the declaration of Helsinki
(1964) and amended in Edinburgh (2000). All subjects were ex-
perienced MDMA users and gave their informed consent to par-
ticipate in the study in writing. Approval for the study was ob-
tained from the Medical Ethics committee of the Academic
Hospital of Maastricht and the University of Maastricht. A per-
mit for purchase, storage, and administration of MDMA was ob-
tained from the Dutch Drug Enforcement Administration.
Samples were taken on four different occasions, 2 h after oral
administration of either MDMA (25, 50, or 100 mg) or placebo.
One participant provided blood and serum samples on only 3 of
the 4 occasions, and 63 samples in total were obtained for blood
and serum. Samples were stored frozen at –20°C for approxi-
mately two weeks until analysis. Hemolyzed blood and corre-
sponding serum were extracted twice on two different occasions
following the protocol described.
Materials
Deuterated (100 µg/mL in methanol) and undeuterated (1
mg/mL in methanol) MDMA and MDA were obtained from
Promochem (Wesel, Germany). High-pressure liquid chro-
matography (HPLC)-grade acetonitrile, methanol, and ethyl
acetate (≥ 99.8%) were purchased from Roth (Karlsruhe, Ger-
many); acetic acid (100%), ammonium acetate (≥ 98%), solid
NaOH, and concentrated HCl were from Merck (Darmstadt,
Germany); and double-distilled water was supplied by Braun
(Melsungen, Germany).
Extraction procedures, instrumentation, and
tandem mass spectrometry (MS) conditions
NaOH (0.1 M) and deuterated standards (10 ng) were added
to a 100-µL aliquot of samples or calibration standards. Sup-
plemented samples were extracted with ethyl acetate and cen-
trifuged. The organic layer was transferred to a silanized vial,
acidified with 50 µL of methanolic hydrochloric acid (MeOH/
HCl, 49:1, v/v), and evaporated. The residue was reconstituted
with mobile phase [50 µL of 4 mM ammonium acetate buffer
(pH 3.2)/methanol/acetonitrile (65:7:28, v/v/v)].
Analysis was performed on an API 4000 tandem MS with a
TurboIon ionization source operated in the positive-ion mode
(Applied Biosystems, Darmstadt, Germany) interfaced to an
HPLC pump equipped with an autosampler (1100 series, Agi-
lent, Waldbronn, Germany). The samples (10-µL aliquots)
were eluted from a Zorbax Eclipse XDB-C8 (2.1 × 150 mm, 5-
µm particle size, Agilent, Waldbronn, Germany) at a flow rate
of 220 µL/min. Data were acquired in multiple reaction mon-
itoring mode (MDMA, m/z 194 → 163; MDA, m/z 180 → 163;
MDMA-d5, m/z 199→ 165; and MDA-d5, m/z 185→ 168). The
transitions were also used for quantification (linear curve fit).
Calibration lines (5–1000 ng/mL for each analyte) were as-
sessed for linearity of response using regression analysis. In
addition, ion suppression or enhancement, carryover, and
benchtop stability (24 h) were checked. The lower limits of de-
tection (LLOD) and quantitation (LLOQ) were estimated from
the calibration curves according to DIN 32465 at a probability
of 95% (17).
Statistical analysis
A regression analysis to calculate the B/S ratio was performed
followed by an analysis of covariances (ANCOVA) to determine
whether the two pools of B/S ratios (experimental and authen-
tic) were significantly different from each other. The analyses
were performed independently for each of the two analytes
using SPSS Version 16.0.1 (SPSS, Chicago, IL).
Results
Method validation
The extraction efficiency for MDMA and MDA was always >
95% of the spiked concentration, for blood and serum. Linear-
ity was given within the calibration range, with correlation co-
efficients r > 0.995 for both MDMA and MDA in blood and
serum. All calibrators were within a 10% range of the target
concentration; standard deviations were below 7%. The LLODs
were 5.5 and 5.6 ng/mL for MDMA and 1.9 and 2.9 ng/mL for
MDA in blood and serum, respectively. Findings where the con-
centrations or either blood or serum or both were below the
LLOD were not considered for calculations; those with concen-
trations between the LLOD and the LLOQ were labeled “posi-
tive” but not considered for calculations either. Ion suppres-
sion/enhancement and carryover could not be observed, and
analytes’ concentration did not decrease within 24 h.
Correlation between hematocrit and
B/S ratio (supplemented samples)
B/S ratios for MDMA and MDA increased with increasing
hematocrit. For MDMA, the ratios ranged from 1.00 to 1.42
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(mean: 1.26, SD: 0.09), for MDA from 0.98 to 1.41 (mean: 1.15,
SD: 0.08). Linear regression analyses through the origin pre-
dicting the whole blood value for a given value of serum re-
vealed regression coefficients of 1.22 (SD: 0.03, R2 = 0.992) for
MDMA and 1.15 (SD: 0.02, R2 = 0.993) for MDA. Adding the
constraint that a value of zero in serum must coincide with a
value of zero in whole blood leads to more clearly robust esti-
mates of B/S ratios.
Authentic samples
MDMA concentrations in the 63 authentic samples ranged
from not detectable to 310 or 236 ng/mL in blood or in serum,
respectively. For all samples where MDMA could be deter-
mined in the serum, it was also present in the blood, and vice
versa. Two samples showed concentrations between the LLOD
and the LLOQ in both serum and blood. The B/S ratio for
MDMA ranged from 0.84 to 1.35, the average being 1.16 ±
0.13. Of the total 42 samples in which MDMA could be deter-
mined and quantified, 36 (86%) showed a B/S ratio > 1.0, and
for 6 samples (14%), the ratio was < 1.0. A simple linear re-
gression through the origin predicting the whole blood value
for a given value of serum revealed a regression coefficient of
1.26 (SD: 0.02, R2 = 0.981) for MDMA. Figure 1 shows a scat-
ter plot with blood and corresponding serum concentrations
in supplemented and authentic samples.
The MDA concentration was between the LLOD and the
LLOQ in 27 serum samples, whereas for the blood samples, a
positive finding could be obtained in 15 cases. MDA concen-
trations were up to 10.4 ng/mL in blood and 16.3 ng/mL in
serum. All 10 samples from which MDA could be determined
and quantified had a B/S ratio > 1.0. The average B/S ratio was
1.27± 0.20 (range: 1.01–1.77). A simple linear regression
through the origin predicting the whole blood value for a
given value of serum revealed a regression coefficient of 1.27
(SD: 0.06, R2 = 0.953) for MDA.
Comparison of supplemented and authentic samples
The B/S ratios were calculated by means of regression for
both studies (supplemented and authentic samples). For MDMA,
the regressions provided slopes (B/S ratios) of 1.22 (confidence
interval 1.16; 1.28) and 1.26 (confidence interval 1.22; 1.30) for
the supplemented and the authentic samples, respectively. For
MDA, the analysis determined slopes of 1.15 (confidence inter-
val 1.11; 1.19) and 1.27 (confidence interval 1.15; 1.39) for the
supplemented and authentic samples, respectively.
An ANCOVA revealed that the method of determination (ex-
perimental vs. authentic) did not influence the resulting
slopes. The differences in slope were 0.03 for MDMA and 0.12
for MDA; neither of them turned out to be significant (MDMA:
p = 0.358, not significant; MDA: p = 0.925, not significant).
Discussion
The B/S ratio for MDMA and MDA using an experimental
setting or authentic human samples has not yet been deter-
mined, to the authors’ knowledge. De Letter et al. (18) re-
ported MDMA blood to plasma (B/P) ratios in rabbits to range,
depending on the time of sampling after intravenous applica-
tion, between 1.2 and 1.3, which comes very close to the val-
ues obtained in the present study. Nonetheless, it is disputable
whether B/P ratios in rabbits after i.v. application can be com-
pared to those in humans after administration of MDMA by
the oral route.
The present study revealed B/S ratios > 1 for both MDMA and
MDA and slightly lower distribution ratios for MDMA than for
MDA, no matter whether results were derived from supple-
mented or authentic samples. A B/S ratio > 1 demonstrates an
additional binding to, or greater solubility in, the red blood cell
than can be accounted for simple distribution in the subcom-
partments of blood. The plasma protein binding of MDMA and
MDA is in a low-to-medium range of 34–40% (19) and thus fa-
vors distribution into erythrocytes. Statistical analysis showed,
that MDMA and MDA partitioning under in vitro and in vivo
conditions gave equivalent results that are in accordance with
passive diffusion of the analytes as the underlying process.
A linear relationship between the hematocrit value and the
B/S ratio of both MDMA [y = 0.0097x + 0.8661, x: hematocrit
value (%), y: B/S ratio] and MDA (y = 0.0083x + 0.8393) could
be established from the experimental data. The hematocrit val-
ues in blood drawn from healthy adults ranges from 35 to 54%
depending on sex (20). Based on the previously mentioned re-
lationship, B/S ratios are expected to range from 1.21 to 1.39
for MDMA and from 1.13 to 1.29 for MDA within the normal
range. These estimates are quite in line with the range of B/S
ratios covered by the authentic samples.
The concentration range found in the authentic samples
(0–310 ng/mL; mean: 78.4 ng/mL; median: 45.6 ng/mL) turns
out to be lower than that found in the blood of DUID suspects
in a study by Jones et al. (21) (mean: 230 ng/mL; median: 100
ng/mL). This can be explained by the lower-range dosage cho-
sen to minimize potential side effects even though the study
participants had previously used MDMA.
In forensic work, serum or plasma is less often analyzed, and
determination of the hematocrit value will generally not be per-
formed. Instead, samples of whole blood are submitted for anal-
ysis, and these are often hemolyzed and sometimes contain
clots. In our case, the hematocrit determination was not possi-
ble in the authentic samples because of beginning hemolysis,
despite the fact that routine phlebotomy protocols were followed
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Figure 1. Concentration of MDMA (ng/mL) in whole blood specimens
(hematocrit values between 26 and 45%) supplemented with 250 ng
MDMA/mL and corresponding serum (open circles, n = 20) and au-
thentic samples from a drug and driving study (black circles, n = 63).
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during sample collection. Thus, the whole blood samples from
the field study largely addressed the conditions of forensic spec-
imens. ANCOVA statistical analysis confirmed the equivalency
of the two methods; the MDMA serum concentration could thus
be estimated from whole blood samples with adequate accuracy
using a factor of 0.80. If it is advisable to consider inherent bio-
logical variations in the B/S relationship, for law enforcement
purposes, for example, the SD or confidence intervals as indi-
cated in the results section should be considered.
For MDA, this process bears certain crucial limitations. The
concentrations determined from field study specimens were
very low, within the first order of magnitude above the limit of
detection. The concentration used in the in vitro setting was
much higher in order to get reliable and quantifiable results. Al-
though the experimental setting would suggest a factor of about
0.80 to calculate the serum concentration on the basis of a
whole blood sample, the distribution of B/S ratios determined
from the authentic samples was scattered over a rather large
range of values (0.55–0.99). Nevertheless, reports of MDA con-
centration being 5–10% of the corresponding MDMA blood or
serum levels could be confirmed, and statistical analysis using
regression analysis followed by ANCOVA revealed that the two
methods are, in fact, not significantly different from each other.
Conclusions
The B/S ratios of MDMA obtained in an experimental setting
are not significantly different from those of healthy volunteers
obtained during a controlled drug and driving study following
administration of MDMA by the oral route. A high correlation
between the hematocrit value and the B/S ratio of both MDMA
and MDA could be established in the experimental setting. Di-
viding the concentration of MDMA in blood by 1.26 gives a rea-
sonably good estimate of the coexisting concentration in
serum. For MDA, higher blood levels would be needed to make
reliable predictions.
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